57th ASH Annual Meeting and Exposition (December 5-8, 2015): 902. Health Services and Outcomes Research – Malignant Diseases: Economic Burdens of Therapy

Health Services and Outcomes Research – Malignant Diseases Oral and Poster Abstracts
Oral

W340, Level 3 (Orange County Convention Center)

Moderators:

Kenneth R Carson, MD, PhD, St Louis Veterans Administration Medical Center and Richard Aplenc, MD, PhD, Children's Hospital of Philadelphia

Disclosures:

No relevant conflicts of interest to declare.

4:30 PM

871

Prevalence and Economic Burden of Chronic Lymphocytic Leukemia (CLL) in the Era of Oral Targeted Therapies

Nitin Jain, MD¹, Qiushi Chen²^*, Turgay Ayer, PhD²^*, Susan M. O'Brien, MD³^*, Michael Keating, MBBS¹, William Wierda, MD, PhD¹, Hagop M. Kantarjian, MD¹ and Chhatwal Jagpreet, PhD⁴^*

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Georgia Institute of Technology, Atlanta, GA
³University of California, Irvine/Chao Family Comprehensive Cancer Center, Orange, CA
⁴Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX

4:45 PM

872

Five-Year Direct Cost of Pediatric Patients with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Stem Cell Transplantation (HSCT): An Analysis from US Payers' Perspective

Richard T. Maziarz, MD¹, Annie Guerin, MSc²^*, Genevieve Gauthier, MSc²^*, Julie Heroux, MSc²^*, Maryia Zhdanava, MSc²^*, Eric Q Wu, PhD², Simu K Thomas, PhD³^* and Lei Chen, MD, PhD³^*

¹Adult Blood and Marrow Stem Cell Transplant Program, Knight Cancer Institute, Oregon Health & Science University, Portland, OR
²Analysis Group, Inc, Boston, MA
³Novartis, East Hanover, NJ

5:00 PM

873

Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US)

Amer M. Zeidan, MBBS, MHS¹, Rong Wang, PhD²^*, Amy J. Davidoff, PhD²^*, Steven D. Gore, MD¹^*, Pamela R Soulos, MPH¹^*, Scott F Huntington, MD MPH¹, Cary P. Gross, MD¹^* and Xiaomei Ma, PhD²^*

¹Yale University School of Medicine, New Haven, CT
²Yale University School of Public Health, New Haven, CT

5:15 PM

874

Multiple Myeloma Patient Experience with Financial Toxicity: Findings from the Cancer Experience Registry

Joanne S. Buzaglo, PhD¹^*, Melissa F. Miller, PhD, MPH¹^*, Clare Karten, MS¹^*, Margaret Longacre, PhD¹^*, Victoria Kennedy, MSW, LCSW¹^* and Thomas W. LeBlanc, MD, MA²

¹Research & Training Institute, Cancer Support Community, Philadelphia, PA
²Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC

5:30 PM

875

Economic Burden of Relapsed or Refractory Multiple Myeloma: Results from an International Trial

Donald Robinson Jr.¹^*, Robert Z. Orlowski, MD, PhD², Jianming He, PhD³^*, Annette Lam³^*, Ning Zhao³^* and Andrew Z Cakana, MB, ChB, Med, Sc, FRCPath⁴

¹Janssen Global Services, LLC, Malvern, PA
²The University of Texas MD Anderson Cancer Center, Houston, TX
³Janssen Global Services, LLC, Raritan, NJ
⁴Janssen Research & Development, High Wycombe, United Kingdom

5:45 PM

876

Economic Burden of Adverse Events Among Patients with Chronic Myelogenous Leukemia Treated with BCR-ABL1 Tyrosine Kinase Inhibitors

Jay Lin, PhD, MBA¹^*, Makenbaeva Dinara, MD, MBA²^*, Bilmes Robyn, PharmD, BCOP²^*, Melissa Lingohr-Smith, PhD¹^* and Nicola Wallis, MRCPath, FFPM²^*

¹Novosys Health, Green Brook, NJ
²Bristol-Myers Squibb, Princeton, NJ

See more of: Health Services and Outcomes Research – Malignant Diseases
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

902.O2.6 902. Health Services and Outcomes Research – Malignant Diseases: Economic Burdens of Therapy